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Low-dosemethotrexate for advancedpulmonary
disease in patients with cystic ¢brosis
M.BALLMANN, S. JUNGE ANDH.VONDERHARDT
Paediatric Department,Medical School Hannover,Hannover,Germany
Abstract Inflammation is a hallmark in the pathogenesis of pulmonary destruction in cystic fibrosis (CF).There is no
proveneffective systemic anti-inflammatory treatment for CF patientswith advancedpulmonarydisease.Methotrexate
(MTX) isknownas aneffective anti-inflammatory treatmentin asthma andinjuvenilerheumatoid arthritis.The question
was: Is an improvement in pulmonary function achievable with low-dose MTX in patients with cystic fibrosis and ad-
vanced pulmonarydisease.?Methods:We treated five CF patientswith advanced pulmonarydisease, who deteriorated
in spite of intensive conventional therapyon anindividualbasiswith low-dose MTX.FEV1% and immunoglobulin G (IgG)
serumlevelswere followed fromtheyear before totheyear after startingwith MTX.Results: Intheyear before starting
with MTX, FEV1% decreased (median: 10% FEV1; range 9^15% FEV1; Po0.005) after starting with MTX, FEV1% in-
creased (median: 9% FEV1; range: 2^15% FEV1; Po0.05). IgG changed (median:2g/l; range: 0.2 to7.3 g/l) in the first
year with MTX.Conclusion:These preliminary data suggest a beneficial effect of MTXeven in advanced pulmonary dis-
ease in CF patients and supports the need for a controlledprospective study.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1471, available online athttp://www.sciencedirect.com
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Cystic ¢brosis (CF) is themost frequent lethal autosomal
recessive inheriteddisease amongCaucasians. In£amma-
tion is a hallmark in the pathogenesis of pulmonary de-
struction in CF. Anti-in£ammatory treatment was
recognised as a potentially important therapeutic tool
(1,2). A slower decrease of FEV1% was demonstrated in
a long-term study (2) with high-dose ibuprofen. This ef-
fect was most pronounced in children younger than 13
years with mild lung disease. There were also bene¢cial
e¡ects of alternate-day systemic steroids (1), but they
are unsuitable for long-term treatment because of the
side-e¡ects (3). Patients with CF and advanced lung dis-
ease may also pro¢t from systemic immunosuppression.
The drug onewants to use should have a proven anti-in-
£ammatory e¡ect and long-term experience regarding
adverse e¡ectsmust be available to estimate the poten-Received 5 February 2002
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known as an e¡ective anti-in£ammatory drug even in
children and there is also some experience with long-
term treatment (i.e. juvenile rheumatoid arthritis (4),
asthma(5)). The adverse e¡ects of low-dose MTX are
tolerable (6). In CF patients who deteriorated in spite of
intensive conventional therapy, we used MTX as an add-
on therapy. The question was: Is a pulmonary improve-
ment with low-dose MTX achievable in patients with
CF and advancedpulmonary disease.
METHODS
Retrospectively the clinical data of ¢ve chronically Pseu-
domonas aeruginosa infectedpatientswithCF (details see
Table1) and advancedpulmonary diseasewhowere trea-
ted on an individual basis with oral MTX were sum-
marised. MTX doses ranged from10 to 20mg/m2 orally
once every week. All patientswere treatedwith intrave-
nous antibiotics routinely every 3months and on exacer-
bations. Systemic steroids (1), ibuprofen (2), azithromycin
(7) or colchicine (8) were not part of the treatment
regimes. There were no changes in the use of rhDNase
or inhaled steroids during the observation period. The
TABLE 1. E¡ects of MTXon FEV1% predicted and IgG serumlevels
N Sex Age
(years)
FEV1%
predicted
IgG serumlevel
(g/l)
MTX
(mg/m2)
Clinical
follow-up
1a 0b 1c 1a 0b 1c
1 M 19.2 30 21 23 13.9 16.3 14.9 11 +3 months later
2 M 8.2 37 22 32 20.1 16.8 17.0 15 MTX stopped after 9 months; died 24 months later
3 F 15.2 27 18 26 24.8 22.2 20.0 13 Lung transplantation 31months later
4 F 18.5 25 d 34 23.2 21.9 19.9 18 Lung transplantation17 months later
5 F 15.4 65 53 68 20.1 23.1 15.8 20 FEV172% inthe third yearwith MTX
aIntheyear before.
bWhen starting.
cIn theyear after startingwith MTX.
dNotmeasurable atthattime
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points indicating severe pulmonary damage. FEV1% pre-
dicted and immunoglobulin G (IgG) serum levels were
followed from the year before to the year after starting
with MTX. The change in FEV1% was the primary out-
come parameter. IgG was used as a systemic marker of
chronic in£ammation.The best value in the year before,
the value when starting MTX and the best value in the
following year was taken.Weused thebest annual values
to exclude actualreversible decreases inpulmonary func-
tion or immune responses. Paired t-test was used to
compare data with/without MTX and Po0.05 was con-
sidered signi¢cant.
RESULTS
In the year before starting with MTX, FEV1% decreased
(median:10.5%; range 9^15% FEV1; Po0.005). In the year
after starting MTX, FEV1% increased (median: 9% Fev1;
range: 2^15% FEV1; Po0.05). In patient number 4, the
FEV1was not measurable when MTX was started (see
Table 1). IgG levels decreased in the year after starting
with MTX in four out of ¢ve patients (see table 1). The
most relevant improvement of FEV1% and IgGwas seen
in patient number 5 who had the best pulmonary func-
tion at the time when MTX was started and she was
treated with the highest dose of MTX compared to the
other four patients. No severe side-e¡ects were ob-
served. One patient reported some nausea on the day
when MTXwas taken during theweek.
DISCUSSION
With the use of MTX, an improvement of pulmonary
function and a trend to a reduction of IgGwere observed
in a highly selectedgroup ofpatientswithCF. All conven-
tional therapeutic options were used before MTX was
added to the treatment regime on an individual basis. Aswith other indications (i.e. juvenile rheumatoid arthritis
(4), asthma (5)) there were responder and non-respon-
der to low-dose MTX. In three out of four patients, the
clinical improvement (increased FEV1%) was accompa-
nied by decreased IgG levels. At this time, we cannot
speculate on a cause/e¡ect relation regarding the higher
dose of MTX in patient number 5 and the more pro-
nounced clinical response compared to the other pa-
tients. In accordance with the e¡ect of ibuprofen (2), it
might be possible that a relative milder pulmonary de-
struction allowedmore improvement. In a subgroup ana-
lysis of patients with steroid-resistant asthmawhowere
treatedwithMTX thoserespondedmorewith a steroid-
sparing e¡ect, whose long-term steroid doses were low
(5).We are aware of the limitations (retrospectivenature
and small number of patients) of this ¢rst report ofMTX
in CF. Nevertheless, these preliminary data suggest a
bene¢cial e¡ectofMTXeven in advancedpulmonarydis-
ease in CF patients and supports the need for a con-
trolled prospective study.
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